• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

RSS Content

MiMedx To Present At Canaccord's 12th Annual Musculoskeletal Conference
COMPANY ALSO TO EXHIBIT AT AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MEETING

MARIETTA, Ga., March 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at Canaccord's 12th Annual Musculoskeletal Conference in San Diego, CA.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Tuesday, March 14, 2017 at 8:30 a.m. Pacific time, at the Westin San Diego.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.

MiMedx will also be exhibiting the Company's human amniotic membrane allograft tissue technologies at the 2017 Annual Meeting of the American Association of Orthopaedic Surgeons. Throughout the conference, MiMedx plans to hold various meetings with physicians, scientists and investors to discuss and demonstrate the benefits and potential of the Company's PURION® Processed allografts.  MiMedx will be located in Booth 1261 at the Orange County Convention Center, Orlando, Florida. 

About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-to-present-at-canaccords-12th-annual-musculoskeletal-conference-300420383.html

SOURCE MiMedx Group, Inc.

Michael Senken, Phone: (770) 651-9100; Investor Contact: COCKRELL GROUP, Rich Cockrell, 877-889-1972, investorrelations@thecockrellgroup.com, cockrellgroup.com

Products

CONTACT US

888.543.1917